Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Sunbelt Rentals Holdings Inc. Common Stock (SUNB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Sunbelt Rentals Holdings Inc. Common Stock — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Sunbelt Rentals Holdings Inc. Common Stock trades at $74.57 (market cap $31.69B). The key difference: Sunbelt Rentals Holdings Inc. Common Stock is far larger — about 11.1× Dyne Therapeutics Inc. Common Stock's market cap, and Sunbelt Rentals Holdings Inc. Common Stock pays a 1.36% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Sunbelt Rentals Holdings Inc. Common Stock for 6 Days on average.
| DYN | SUNB | |
|---|---|---|
Market Cap | $2.86B | $31.69B |
Volume | 3,341,579 | 3,330,792 |
Sector | Health | Industrials |
52-Week High | $26.78 | $86.06 |
52-Week Low | $14.60 | $63.09 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $2.18B | $43.08B |
Dividend Yield | — | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
SUNB trades at $77.33, up 2.34% with neutral technical signals. The company reported strong Q2 2026 earnings beat ($1.18 vs $0.99 expected) and raised FY2027 guidance. Valuation metrics show P/E of 23.08 and ROE of 18.37%, with revenue growth from $10.79B to $11.5B projected. Recent institutional buying includes State Street Corp's $441M investment in Q2 2026.
Outlook remains positive with analyst consensus target of $86.83 (12.3% upside). Key opportunities include infrastructure demand and specialty equipment rental growth, while risks involve significant debt load ($7.5B) and declining free cash flow. The stock presents a balanced risk-reward profile with moderate growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Sunbelt Rentals Holdings Inc. Common Stock
Sunbelt Rentals provides equipment rentals and related services in the United States, Canada, and the United Kingdom. Its fleet includes general and specialty equipment for construction, industrial, infrastructure, and maintenance projects.
Read more on SUNB →
